Dexlansoprazole

• CAT Number: A000879
• CAS Number: 138530-94-6
• Molecular Formula: C16H14F3N3O2S
• Molecular Weight: 369.4
• Purity: ≥95%
• Synonyms: Dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Dexilant; R-(+)-LANSOPRAZOLE; Kapidex
• Target: Proton Pump
• Storage: -20°C
• InChI: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
• InChIKey: MJIHNNLFOKEZEW-RUZDIDTESA-N
• SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F

Dexlansoprazole, also known as Dexilant and TAK-390MR, is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosive gastroesophageal reflux disease.

Reference

1: Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and
14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement
for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A
Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev. 2017
Oct 26;18(10):2839-2843. PubMed PMID: 29072432.

2: Park HY, Kang EJ, Kim DG, Kim KJ, Choi JW, Nam SY, Kwon YH, Lee HS, Jeon SW.
High and Frequent Dose of Dexlansoprazole and Amoxicillin Dual Therapy for
Helicobacter pylori Infections: A Single Arm Prospective Study. Korean J
Gastroenterol. 2017 Oct 25;70(4):176-180. doi: 10.4166/kjg.2017.70.4.176. PubMed
PMID: 29060955.

3: Sun LN, Cao Y, Li YQ, Fang YQ, Zhang HW, Wang MF, Xie LJ, Chen J, Yang ZC,
Bian ML, Li H, Zhang PP, Wei JF, Meng L, Zhang XH, Zhao P, Wang YQ. Impact of
Gastric H(+)/K(+)-ATPase rs2733743 on the Intragastric pH-Values of
Dexlansoprazole Injection in Chinese Subjects. Front Pharmacol. 2017 Sep
22;8:670. doi: 10.3389/fphar.2017.00670. eCollection 2017. PubMed PMID: 29018343;
PubMed Central PMCID: PMC5614982.

4: Gold BD, Pilmer B, Kierkuś J, Hunt B, Perez MC, Gremse D. Dexlansoprazole for
Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal
Reflux Disease. Dig Dis Sci. 2017 Nov;62(11):3059-3068. doi:
10.1007/s10620-017-4743-3. Epub 2017 Sep 15. PubMed PMID: 28916953; PubMed
Central PMCID: PMC5649596.

5: Chung HK, Truong QK, Mai XL, Choi Y, Kang JS, Mar W, Kim KH. Determination of
S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone
electrophoresis. Arch Pharm Res. 2017 Aug;40(8):962-971. doi:
10.1007/s12272-017-0936-8. Epub 2017 Aug 1. PubMed PMID: 28766240.

6: Kukulka M, Nudurupati S, Perez MC. Bioavailability of a dexlansoprazole
delayed-release orally disintegrating tablet: effects of food and mode of
administration. Clin Exp Gastroenterol. 2017 Feb 17;10:47-56. doi:
10.2147/CEG.S121129. eCollection 2017. PubMed PMID: 28255251; PubMed Central
PMCID: PMC5323062.

7: Fass R, Frazier R. The role of dexlansoprazole modified-release in the
management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017
Feb;10(2):243-251. doi: 10.1177/1756283X16681701. Epub 2017 Jan 5. Review. PubMed
PMID: 28203282; PubMed Central PMCID: PMC5298478.

8: Li YQ, Yan ZY, Zhang HW, Sun LN, Jiao HW, Wang MF, Yu LY, Yu L, Yuan ZQ, Meng
L, Wang YQ. Safety, tolerability, pharmacokinetics and pharmacodynamics of
dexlansoprazole injection in healthy Chinese subjects. Eur J Clin Pharmacol. 2017
May;73(5):547-554. doi: 10.1007/s00228-017-2206-6. Epub 2017 Jan 31. PubMed PMID:
28138748.

9: Kukulka M, Nudurupati S, Perez MC. Bioavailability, safety, and
pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg
orally disintegrating tablets or one 60 mg capsule. Therap Adv Gastroenterol.
2016 Nov;9(6):770-780. Epub 2016 Sep 25. PubMed PMID: 27803732; PubMed Central
PMCID: PMC5076775.

10: Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and pharmacodynamics of
an orally disintegrating tablet formulation of dexlansoprazole. Therap Adv
Gastroenterol. 2016 Nov;9(6):759-769. Epub 2016 Sep 29. PubMed PMID: 27803731;
PubMed Central PMCID: PMC5076779.